Dr. Nami is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
332 Lillington Ave
Charlotte, NC 28204Phone+1 704-377-1216
Summary
- Dr. Alireza Nami, based in Charlotte, NC, specializes in Rheumatology with subspecialties in Lupus, Rheumatoid Arthritis, and Spondyloarthropathy. He completed his residency and fellowship at Albany Medical Center and got his degree from St. George's University School of Medicine. He's currently the Principal Investigator and Owner at Joint and Muscle Research Institute and a Principal Investigator at Novant Health Presbyterian Medical Center. He has past experiences as an instructor. He's experienced in treating dermatomyositis and various forms of lupus, and has made significant contributions to clinical trials and research, with published works cited multiple times. He is honored with membership in prestigious organizations and fellowships, such as the American Board of Internal Medicine and the American College of Rheumatology.
Education & Training
- Albany Medical CenterFellowship, Rheumatology, 1998 - 2000
- Albany Medical CenterResidency, Internal Medicine, 1995 - 1998
- St. George's University School of MedicineClass of 1994
Certifications & Licensure
- NC State Medical License 2004 - 2025
- SC State Medical License 2005 - 2007
- AL State Medical License 2000 - 2004
- American Board of Internal Medicine Rheumatology
- american board of internal MedicineABIM
- GCP/ICHGood Clinical Practice
Awards, Honors, & Recognition
- American Board of Internal Medicine
- Fellow (FACR) American College of Rheumatology
- Member EULAR, 2011-2016
- Join now to see all
Clinical Trials
- A Study of LY2127399 in Participants With Systemic Lupus Erythematosus Start of enrollment: 2010 Dec 01
- Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE) Start of enrollment: 2010 Dec 01
- Clinical Trial Treatment in Lupus Nephritis Start of enrollment: 2011 Feb 01
- Join now to see all
Publications & Presentations
PubMed
- 19 citationsMortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multic...Saira Z Sheikh, Morton A Scheinberg, James Cheng-Chung Wei, Dana Tegzova, William Stohl
The Lancet. Rheumatology. 2021-02-01 - 9 citationsPharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interfer...Ian N Bruce, Alireza Nami, Erik Schwetje, M Edward Pierson, Tomas Rouse
The Lancet. Rheumatology. 2021-02-01
Books/Book Chapters
Authored Content
- JMMCRI11/25/2018
Press Mentions
- RheumatismJanuary 20th, 2023
Grant Support
- ImmunologyPfizer2015–Present
Committees
- Fellow, European League of Rheumatism (EULAR) 2011 - Present
Research History
- Medical research DirectorPrincipal investigator, and Medical Director at Joint and and muscle research institute conducting clinical trials, phase 23 and 4 and selective phase 0 and 1 studies in rheumatism2000 - 2023
Professional Memberships
- Fellow
- Member
Other Languages
- Spanish, French, Russian, Farsi
Industry Relationships
- Medical Adviser, AstraZenecaClinical trials on Anifrolumab for treatment of lupus2020 - 2022
External Links
- Joint And Muscle Medical Care, PChttp://Www.jmmcri.com
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: